Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

Challenges With PARP Inhibitors in Ovarian CancerПодробнее

Dr. Moore on Treatment for Patients With Ovarian Cancer Who Develop Resistance to PARP InhibitorsПодробнее

Dr. Moore on Immunotherapy and PARP Combinations in BRCA-Mutated Ovarian CancerПодробнее

Differences Among PARP Inhibitors in Ovarian CancerПодробнее

Dr. Moore on the NOVA Trial for Ovarian CancerПодробнее

Dr. Moore on the Impact of SOLO-1 in Ovarian CancerПодробнее

Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian CancerПодробнее

Dr. Naumann on Unanswered Questions With PARP Inhibitors in Ovarian CancerПодробнее

Dr. Moore on Research Evaluating Repeat Exposure to PARP Inhibition in Ovarian CancerПодробнее

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. Konecny on the Value of PARP Inhibitors in Ovarian CancerПодробнее

PARP inhibitors for ovarian cancerПодробнее

Recurrent Ovarian Cancer: PARP Inhibitors ComparedПодробнее

Ongoing PARP Inhibitor Research in Ovarian CancerПодробнее

Dr. Copeland on the Use of PARP Inhibitors in Ovarian CancerПодробнее

Everything You Want to Know About PARP InhibitorsПодробнее

Dr. Moore on the Prevalence of Ovarian CancerПодробнее

Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Ongoing PARP Trials in Recurrent Ovarian CancerПодробнее